\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ is\\ remarkable\\ only\\ for\\ focal\\ back\\ pain\\,\\ there\\ was\\ no\\ cervical\\ or\\ supraclavicular\\ adenopathy\\.\\ patient\\ was\\ afebrile\\ with\\ stable\\ vital\\ signs\\.\\ ca\\-125\\ of\\ 48\\ and\\ ldh\\ of\\ 740\\ were\\ both\\ elevated\\.\ \(0\)\
\-\ chemotherapy\\ chop\\-rituximab\\ six\\ cycles\\.\\ evaluation\\ for\\ adjuvant\\ radiation\\ thereapy\\ may\\ be\\ warranted\\.\ \(0\)\
\-\ mri\\ showed\\ l3\\ compression\\ fracture\\ and\\ large\\ pelvic\\ mass\\.\\ subsequent\\ ct\\ with\\ contrast\\ revealed\\ a\\ 12\\ x18\\ heterogeneous\\ multiloculated\\ pelvic\\ mass\\ with\\ adjacent\\ collections\\ of\\ low\\ density\\ free\\ fluid\\,\\ a\\ soft\\ tissue\\ density\\ mass\\ measuring\\ 4\\ x\\ 7\\.4\\ cm\\ at\\ superior\\ pole\\ of\\ right\\ kidney\\ and\\ a\\ 7\\.6\\ x\\ 7\\.2\\ cm\\ fluid\\-filled\\ collection\\ anterior\\ to\\ ascending\\ colon\\.\\ an\\ aortocaval\\ lymphnode\\ measuring\\ 12x13\\ mm\\ and\\ additional\\ sub\\-centimeter\\ nodes\\ were\\ identified\\.\\ interval\\ ct\\ evaluation\\ after\\ second\\ cycle\\ of\\ chop\\-r\\ treatment\\ showed\\ complete\\ resolution\\ of\\ right\\ renal\\ mass\\,\\ interval\\ decrease\\ of\\ aortocaval\\ node\\,\\ and\\ interval\\ decrease\\ of\\ pelvic\\ mass\\ now\\ measuring\\ 12\\.7\\ x\\ 7\\.2\\ cm\\.\\ the\\ l3\\ compression\\ fracture\\ is\\ stable\\.\ \(0\)\
\-\ diffuse\\ large\\ b\\-cell\\ lymphoma\ \(1\)\
\-\ \\(1\\)\\ ovarian\\ carcinoma\\ \\(2\\)\\ acute\\ leukemia\\,\\ 3\\)\\ hepatocellular\\ carcinoma\\,\\ 4\\)\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\,\\ \\(5\\)\\ pancreatic\\ tumor\ \(0\)\
\-\ this\\ 50\\-year\\-old\\ post\\ menopausal\\ woman\\ presented\\ with\\ progressive\\ back\\ pain\\ of\\ two\\ months\\ duration\\ with\\ worsening\\ after\\ a\\ fall\\ two\\ weeks\\ ago\\.\\ \\ she\\ reports\\ night\\ sweats\\ but\\ no\\ fever\\,\\ chills\\ or\\ weight\\ loss\\.\\ \\ she\\ also\\ reports\\ some\\ lower\\ extremity\\ weakness\\.\ \(0\)\
\-\ mri\\ of\\ spine\\ showed\\ l3\\ compression\\ fracture\\ and\\ incidental\\ finding\\ of\\ a\\ large\\ pelvic\\ mass\\.\\ she\\ reports\\ night\\ sweats\\ but\\ no\\ fever\\,\\ chills\\ or\\ weight\\ loss\\.\\ the\\ mass\\ was\\ worrisome\\ for\\ malignancy\\.\\ the\\ patient\\ also\\ reports\\ some\\ low\\ extremity\\ weakness\\.\\ \\ the\\ patient\\ has\\ an\\ ipi\\ \\(international\\ prognostic\\ index\\)\\ of\\ 3\\,\\ meeting\\ criteria\\ for\\ ldh\\,\\ stage\\,\\ and\\ extra\\-nodal\\ disease\\ and\\ thus\\ appears\\ to\\ have\\ a\\ poor\\ prognosis\\.\\ in\\ the\\ presence\\ of\\ a\\ pathological\\ bone\\ fracture\\ \\(l3\\)\\ the\\ patient\\â\\€\\™s\\ clinical\\ condition\\ raises\\ the\\ suspicion\\ whether\\ this\\ may\\ either\\ be\\ due\\ to\\ primary\\ or\\ secondary\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\ of\\ the\\ bone\\.\\ in\\ a\\ retrospective\\ study\\ of\\ 23\\ patients\\ with\\ primary\\ non\\ hodgkin\\â\\€\\™s\\ lymphoma\\ of\\ the\\ bone\\ \\(plb\\)\\ it\\ was\\ found\\ that\\ most\\ were\\ due\\ to\\ diffuse\\ large\\ b\\-cell\\ lymphoma\\ and\\ three\\ cases\\ involved\\ pathologic\\ bone\\ fractures\\.\\ according\\ to\\ this\\ study\\ computed\\ tomography\\ and\\ roentgenography\\ alone\\ were\\ not\\ sufficient\\ to\\ diagnose\\ plb\\ and\\ that\\ diagnosis\\ must\\ be\\ confirmed\\ according\\ to\\ clinical\\ features\\ \\(localized\\ pain\\ and\\ tenderness\\)\\,\\ pathological\\ findings\\ and\\ immunohistochemistry\\ assay\\ \\[4\\]\\.\\ our\\ patient\\ meets\\ these\\ confirmatory\\ measures\\ and\\ given\\ the\\ fact\\ that\\ the\\ therapeutic\\ procedure\\ for\\ plb\\ mainly\\ includes\\ local\\ radiation\\ therapy\\ combined\\ with\\ chemotherapy\\,\\ our\\ patient\\ may\\ best\\ benefit\\ from\\ adjunctive\\ radiotherapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plb\\:\\ 0\\.24182855227067132\ \(0\)\
\-\ l3\\:\\ 0\\.1999406415569928\ \(0\)\
\-\ of\\:\\ 0\\.15782642484592663\ \(0\)\
\-\ pelvic\\:\\ 0\\.1576074792150498\ \(0\)\
\-\ reports\\:\\ 0\\.1567835424557075\ \(0\)\
\-\ hodgkin\\:\\ 0\\.15445932875613494\ \(0\)\
\-\ aortocaval\\:\\ 0\\.1540533946576075\ \(0\)\
\-\ lymphoma\\:\\ 0\\.15009826039879112\ \(0\)\
\-\ and\\:\\ 0\\.14581978312509564\ \(0\)\
\-\ interval\\:\\ 0\\.1368314953218473\ \(0\)\
\-\ mass\\:\\ 0\\.1347751380436299\ \(0\)\
\-\ measuring\\:\\ 0\\.11698378187226398\ \(0\)\
\-\ fracture\\:\\ 0\\.11458894699323358\ \(0\)\
\-\ compression\\:\\ 0\\.11073622095142151\ \(0\)\
\-\ the\\:\\ 0\\.11063516578582983\ \(0\)\
\-\ bone\\:\\ 0\\.11001145153841659\ \(0\)\
\-\ ldh\\:\\ 0\\.10965431373179653\ \(0\)\
\-\ pathological\\:\\ 0\\.10505442340271322\ \(0\)\
\-\ were\\:\\ 0\\.10393050799945291\ \(0\)\
\-\ sweats\\:\\ 0\\.1029728858374233\ \(0\)\
\-\ according\\:\\ 0\\.1014079132412167\ \(0\)\
\-\ large\\:\\ 0\\.10102281798825345\ \(0\)\
\-\ showed\\:\\ 0\\.10072106802759638\ \(0\)\
\-\ patient\\:\\ 0\\.09836645499163638\ \(0\)\
\-\ chills\\:\\ 0\\.09173328327791545\ \(0\)\
\-\ night\\:\\ 0\\.09056026036644516\ \(0\)\
\-\ she\\:\\ 0\\.09001574683310753\ \(0\)\
\-\ our\\:\\ 0\\.08930857680946107\ \(0\)\
\-\ to\\:\\ 0\\.08820909563846328\ \(0\)\
\-\ cm\\:\\ 0\\.08684551249378697\ \(0\)\
\-\ decrease\\:\\ 0\\.08664918065369864\ \(0\)\
\-\ thereapy\\:\\ 0\\.08060951742355711\ \(0\)\
\-\ ipi\\:\\ 0\\.08060951742355711\ \(0\)\
\-\ roentgenography\\:\\ 0\\.08060951742355711\ \(0\)\
\-\ stable\\:\\ 0\\.07974536218939117\ \(0\)\
\-\ 740\\:\\ 0\\.07702669732880375\ \(0\)\
\-\ x18\\:\\ 0\\.07702669732880375\ \(0\)\
\-\ 12x13\\:\\ 0\\.07702669732880375\ \(0\)\
\-\ for\\:\\ 0\\.07638774279810318\ \(0\)\
\-\ may\\:\\ 0\\.07609705220952685\ \(0\)\
\-\ weakness\\:\\ 0\\.07357435313225398\ \(0\)\
\-\ extremity\\:\\ 0\\.07260905419451769\ \(0\)\
\-\ immunohistochemistry\\:\\ 0\\.07251287783325425\ \(0\)\
\-\ meets\\:\\ 0\\.07251287783325425\ \(0\)\
\-\ non\\:\\ 0\\.07174928847375035\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.07158261226659786\ \(0\)\
\-\ lymphnode\\:\\ 0\\.07090182592194197\ \(0\)\
\-\ assay\\:\\ 0\\.07090182592194197\ \(0\)\
\-\ weight\\:\\ 0\\.07030065031469794\ \(0\)\
\-\ was\\:\\ 0\\.07026739357028419\ \(0\)\
\-\ or\\:\\ 0\\.07014083382584509\ \(0\)\
\-\ with\\:\\ 0\\.0690903176675093\ \(0\)\
\-\ 12\\:\\ 0\\.0689138494529254\ \(0\)\
\-\ menopausal\\:\\ 0\\.06835977460983356\ \(0\)\
\-\ adjunctive\\:\\ 0\\.06835977460983356\ \(0\)\
\-\ fever\\:\\ 0\\.06835127749928208\ \(0\)\
\-\ meeting\\:\\ 0\\.06731900582718858\ \(0\)\
\-\ back\\:\\ 0\\.06723379765046833\ \(0\)\
\-\ study\\:\\ 0\\.06723379765046833\ \(0\)\
\-\ density\\:\\ 0\\.06684819741069116\ \(0\)\
\-\ radiation\\:\\ 0\\.06680586770611974\ \(0\)\
\-\ confirmatory\\:\\ 0\\.06638800642639246\ \(0\)\
\-\ that\\:\\ 0\\.06562241194346816\ \(0\)\
\-\ worrisome\\:\\ 0\\.06477695451508017\ \(0\)\
\-\ clinical\\:\\ 0\\.0638893913105997\ \(0\)\
\-\ some\\:\\ 0\\.0634294166735012\ \(0\)\
\-\ diffuse\\:\\ 0\\.0632210923373257\ \(0\)\
\-\ cycles\\:\\ 0\\.06280518633163909\ \(0\)\
\-\ primary\\:\\ 0\\.06198800457348416\ \(0\)\
\-\ evaluation\\:\\ 0\\.06148031743335438\ \(0\)\
\-\ loss\\:\\ 0\\.06141786986586991\ \(0\)\
\-\ be\\:\\ 0\\.061342602597587524\ \(0\)\
\-\ international\\:\\ 0\\.0611941344203268\ \(0\)\
\-\ raises\\:\\ 0\\.0611941344203268\ \(0\)\
\-\ retrospective\\:\\ 0\\.06071637906490681\ \(0\)\
\-\ carcinoma\\:\\ 0\\.06030069559502068\ \(0\)\
\-\ two\\:\\ 0\\.05986716666342162\ \(0\)\
\-\ multiloculated\\:\\ 0\\.05902815354859755\ \(0\)\
\-\ prognostic\\:\\ 0\\.05902815354859755\ \(0\)\
\-\ adjuvant\\:\\ 0\\.05865208310821839\ \(0\)\
\-\ fluid\\:\\ 0\\.058206158659369324\ \(0\)\
\-\ due\\:\\ 0\\.05794815928591189\ \(0\)\
\-\ cycle\\:\\ 0\\.05794480000109906\ \(0\)\
\-\ low\\:\\ 0\\.0578460049944847\ \(0\)\
\-\ mainly\\:\\ 0\\.0566803149247773\ \(0\)\
\-\ warranted\\:\\ 0\\.05639057350495019\ \(0\)\
\-\ diagnose\\:\\ 0\\.05639057350495019\ \(0\)\
\-\ sufficient\\:\\ 0\\.05557433314057289\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.05506926301346502\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.054591507658045026\ \(0\)\
\-\ pain\\:\\ 0\\.05411092909769756\ \(0\)\
\-\ benefit\\:\\ 0\\.053499214988282154\ \(0\)\
\-\ index\\:\\ 0\\.0521664954292278\ \(0\)\
\-\ this\\:\\ 0\\.0519608090273363\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.05181992859423728\ \(0\)\
\-\ mri\\:\\ 0\\.0517475184749681\ \(0\)\
\-\ therapeutic\\:\\ 0\\.05100868756329165\ \(0\)\
\-\ criteria\\:\\ 0\\.0499851603892482\ \(0\)\
\-\ combined\\:\\ 0\\.0499851603892482\ \(0\)\
\-\ but\\:\\ 0\\.049851289557064485\ \(0\)\
\-\ remarkable\\:\\ 0\\.0497132521169568\ \(0\)\
\-\ alone\\:\\ 0\\.04958037259631075\ \(0\)\
\-\ collections\\:\\ 0\\.049320462046982386\ \(0\)\
\-\ whether\\:\\ 0\\.049320462046982386\ \(0\)\
\-\ no\\:\\ 0\\.049173976417443276\ \(0\)\
\-\ ascending\\:\\ 0\\.04906797853873406\ \(0\)\
\-\ after\\:\\ 0\\.04890515945663631\ \(0\)\
\-\ tomography\\:\\ 0\\.04882250937624383\ \(0\)\
\-\ duration\\:\\ 0\\.04858367533447442\ \(0\)\
\-\ computed\\:\\ 0\\.04858367533447442\ \(0\)\
\-\ fact\\:\\ 0\\.048351127134410435\ \(0\)\
\-\ suspicion\\:\\ 0\\.04790362282395827\ \(0\)\
\-\ also\\:\\ 0\\.04741869323754489\ \(0\)\
\-\ thus\\:\\ 0\\.04631077137552708\ \(0\)\
\-\ leukemia\\:\\ 0\\.046041624022366015\ \(0\)\
\-\ pancreatic\\:\\ 0\\.045695057187375494\ \(0\)\
\-\ six\\:\\ 0\\.04528013018322258\ \(0\)\
\-\ localized\\:\\ 0\\.04528013018322258\ \(0\)\
\-\ vital\\:\\ 0\\.04488381615642987\ \(0\)\
\-\ prognosis\\:\\ 0\\.04435724122044858\ \(0\)\
\-\ pole\\:\\ 0\\.04392959382083526\ \(0\)\
\-\ 48\\:\\ 0\\.04365557739593819\ \(0\)\
\-\ afebrile\\:\\ 0\\.0435216911738835\ \(0\)\
\-\ local\\:\\ 0\\.04338980332840877\ \(0\)\
\-\ node\\:\\ 0\\.04332459032684932\ \(0\)\
\-\ must\\:\\ 0\\.0431955906401206\ \(0\)\
\-\ ovarian\\:\\ 0\\.04294310713187228\ \(0\)\
\-\ nodes\\:\\ 0\\.04281952019974145\ \(0\)\
\-\ poor\\:\\ 0\\.042517909978123526\ \(0\)\
\-\ adenopathy\\:\\ 0\\.042400090611233905\ \(0\)\
\-\ fall\\:\\ 0\\.041999670963921404\ \(0\)\
\-\ pe\\:\\ 0\\.041670328932835\ \(0\)\
\-\ either\\:\\ 0\\.041670328932835\ \(0\)\
\-\ 23\\:\\ 0\\.041563220692883936\ \(0\)\
\-\ pathologic\\:\\ 0\\.04130099606167649\ \(0\)\
\-\ measures\\:\\ 0\\.04109667894506627\ \(0\)\
\-\ resolution\\:\\ 0\\.04089697956203196\ \(0\)\
\-\ collection\\:\\ 0\\.04070169378835724\ \(0\)\
\-\ features\\:\\ 0\\.040558010596473244\ \(0\)\
\-\ best\\:\\ 0\\.040558010596473244\ \(0\)\
\-\ involved\\:\\ 0\\.040416626434550115\ \(0\)\
\-\ condition\\:\\ 0\\.04027746888763304\ \(0\)\
\-\ procedure\\:\\ 0\\.0401858999686653\ \(0\)\
\-\ stage\\:\\ 0\\.04014046890918103\ \(0\)\
\-\ free\\:\\ 0\\.03923670010498807\ \(0\)\
\-\ includes\\:\\ 0\\.039195885613926874\ \(0\)\
\-\ additional\\:\\ 0\\.039074561214545514\ \(0\)\
\-\ progressive\\:\\ 0\\.038605265717698733\ \(0\)\
\-\ an\\:\\ 0\\.03854985955439317\ \(0\)\
\-\ worsening\\:\\ 0\\.03849173539874065\ \(0\)\
\-\ ct\\:\\ 0\\.03837976542893682\ \(0\)\
\-\ colon\\:\\ 0\\.03837964524954958\ \(0\)\
\-\ subsequent\\:\\ 0\\.03815964247624883\ \(0\)\
\-\ second\\:\\ 0\\.037735417575524635\ \(0\)\
\-\ malignancy\\:\\ 0\\.037735417575524635\ \(0\)\
\-\ incidental\\:\\ 0\\.0373636627990187\ \(0\)\
\-\ fractures\\:\\ 0\\.037264931921546986\ \(0\)\
\-\ confirmed\\:\\ 0\\.03716729201532238\ \(0\)\
\-\ appears\\:\\ 0\\.03691207365047384\ \(0\)\
\-\ ago\\:\\ 0\\.03688068348742837\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.03648244562344369\ \(0\)\
\-\ presence\\:\\ 0\\.03621689343745968\ \(0\)\
\-\ cervical\\:\\ 0\\.036101384320686866\ \(0\)\
\-\ mm\\:\\ 0\\.036072741437893005\ \(0\)\
\-\ identified\\:\\ 0\\.03573607894349268\ \(0\)\
\-\ kidney\\:\\ 0\\.03541177386266795\ \(0\)\
\-\ complete\\:\\ 0\\.0353325238103333\ \(0\)\
\-\ signs\\:\\ 0\\.03522795073654644\ \(0\)\
\-\ given\\:\\ 0\\.034673925793891246\ \(0\)\
\-\ now\\:\\ 0\\.03460099837907917\ \(0\)\
\-\ elevated\\:\\ 0\\.034362164337309764\ \(0\)\
\-\ cases\\:\\ 0\\.033903031373618525\ \(0\)\
\-\ three\\:\\ 0\\.033836173640252605\ \(0\)\
\-\ right\\:\\ 0\\.03342307967396316\ \(0\)\
\-\ spine\\:\\ 0\\.033297863392674994\ \(0\)\
\-\ finding\\:\\ 0\\.033132306857012975\ \(0\)\
\-\ revealed\\:\\ 0\\.03305067743950426\ \(0\)\
\-\ superior\\:\\ 0\\.03277077054668537\ \(0\)\
\-\ adjacent\\:\\ 0\\.03267291437933165\ \(0\)\
\-\ found\\:\\ 0\\.03261471666113282\ \(0\)\
\-\ tenderness\\:\\ 0\\.03161054616866285\ \(0\)\
\-\ only\\:\\ 0\\.03149055547670407\ \(0\)\
\-\ renal\\:\\ 0\\.031388987443451116\ \(0\)\
\-\ weeks\\:\\ 0\\.03020906111388907\ \(0\)\
\-\ focal\\:\\ 0\\.03015034779751034\ \(0\)\
\-\ secondary\\:\\ 0\\.029876666409610547\ \(0\)\
\-\ presented\\:\\ 0\\.02939368709802022\ \(0\)\
\-\ months\\:\\ 0\\.02934013346982558\ \(0\)\
\-\ therapy\\:\\ 0\\.028961282650705147\ \(0\)\
\-\ these\\:\\ 0\\.028464030705297922\ \(0\)\
\-\ patients\\:\\ 0\\.028355903055010036\ \(0\)\
\-\ anterior\\:\\ 0\\.02814353797553008\ \(0\)\
\-\ both\\:\\ 0\\.028108634750670346\ \(0\)\
\-\ is\\:\\ 0\\.02760782850180121\ \(0\)\
\-\ post\\:\\ 0\\.027427292172029445\ \(0\)\
\-\ acute\\:\\ 0\\.027267499000104705\ \(0\)\
\-\ soft\\:\\ 0\\.026834865384968307\ \(0\)\
\-\ tissue\\:\\ 0\\.026441638251973907\ \(0\)\
\-\ tumor\\:\\ 0\\.02636504993627785\ \(0\)\
\-\ woman\\:\\ 0\\.026251397930880858\ \(0\)\
\-\ most\\:\\ 0\\.026232597239522943\ \(0\)\
\-\ diagnosis\\:\\ 0\\.02612990243582601\ \(0\)\
\-\ it\\:\\ 0\\.02580191882872519\ \(0\)\
\-\ lower\\:\\ 0\\.025757313375072206\ \(0\)\
\-\ have\\:\\ 0\\.025180358806597785\ \(0\)\
\-\ in\\:\\ 0\\.025078551614976595\ \(0\)\
\-\ findings\\:\\ 0\\.024877182198528226\ \(0\)\
\-\ contrast\\:\\ 0\\.024491048755575607\ \(0\)\
\-\ treatment\\:\\ 0\\.024010858816422138\ \(0\)\
\-\ has\\:\\ 0\\.023023806439958248\ \(0\)\
\-\ disease\\:\\ 0\\.021158477501716386\ \(0\)\
\-\ there\\:\\ 0\\.020056229243121452\ \(0\)\
\-\ from\\:\\ 0\\.020018964784710467\ \(0\)\
\-\ not\\:\\ 0\\.019898929312044983\ \(0\)\
\-\ at\\:\\ 0\\.019038830803654466\ \(0\)\
